Armistice Capital, LLC Macrogenics Inc Transaction History

Armistice Capital, LLC

$7.69 Billion
Q2 2024

A detailed history of Armistice Capital, LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Armistice Capital, LLC holds 6,000,000 shares of MGNX stock, worth $22.2 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares

6,000,000

Previous 2,400,000 150.0%

Holding current value

$22.2 Million

Previous $35.3 Million 27.82%

% of portfolio

0.33%

Previous 0.48%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.31 - $18.51 $11.9 Million - $66.6 Million	3,600,000 Added 150.0%	6,000,000 $25.5 Million
Q1 2024 May 15, 2024	SELL	$9.77 - $21.47 $21.2 Million - $46.6 Million	-2,172,000 Reduced 47.51%	2,400,000 $35.3 Million
Q4 2023 Feb 13, 2024	SELL	$4.48 - $10.11 $627,200 - $1.42 Million	-140,000 Reduced 2.97%	4,572,000 $44 Million
Q3 2023 Nov 14, 2023	SELL	$4.48 - $6.19 $3.98 Million - $5.5 Million	-888,000 Reduced 15.86%	4,712,000 $22 Million
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $1.66 Million - $2.71 Million	-360,000 Reduced 6.04%	5,600,000 $30 Million
Q1 2023 May 15, 2023	SELL	$4.82 - $7.24 $636,240 - $955,680	-132,000 Reduced 2.17%	5,960,000 $42.7 Million
Q4 2022 Feb 14, 2023	SELL	$3.34 - $6.98 $120,240 - $251,280	-36,000 Reduced 0.59%	6,092,000 $40.9 Million
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $2.54 Million - $11.3 Million	1,128,000 Added 22.56%	6,128,000 $18.1 Million
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $18.7 Million - $38.9 Million	2,300,000 Added 85.19%	5,000,000 $44.1 Million
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $43 Million - $59.1 Million	2,700,000 New	2,700,000 $43.3 Million

Others Institutions Holding MGNX

# of Institutions

154

Shares Held

60.6M

Call Options Held

218K

Put Options Held

259K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $227M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Account

Armistice Capital, LLC Macrogenics Inc Transaction History